Functional mitral regurgitation is a disease of the left heart as opposed to the valve leaflets themselves. Two thirds of patients with heart failure have moderate or severe functional mitral regurgitation.1 In these patients, left ventricular dysfunction and remodeling cause papillary muscle displacement and mitral annular dilatation; these…

​   The New England Journal of Medicine: Search Results in Cardiology

SARS-CoV-2 continues to evolve under immunologic pressure. A synthesized version of pemivibart, an anti–SARS-CoV-2 monoclonal antibody with recent emergency-use authorization, showed mixed activity against emerging variants.

​   The New England Journal of Medicine: Search Results in Allergy/Immunology

Pemivibart, a monoclonal antibody for preexposure prophylaxis for SARS-CoV-2, was recently authorized for emergency use by the FDA. The immunobridging data on which this EUA is based are presented.

​   The New England Journal of Medicine: Search Results in Allergy/Immunology

Over the past decade, the use of immune checkpoint inhibitors and antibody–drug conjugates has led to longer survival in patients with metastatic bladder cancer. Platinum-based chemotherapy had been the standard of care for decades. The combination of enfortumab vedotin, an antibody–drug conjugate directed against nectin-4, and pembrolizumab, a programmed death…

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

A full-term infant was admitted to the neonatal intensive care unit for hypoxemic respiratory failure. During the third week, a chest radiograph showed a persistent opacity in the left lower lobe. A diagnosis was made.

​   The New England Journal of Medicine: Search Results in Pulmonary/Critical Care